A064550 Stock Overview
Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A064550 from our risk checks.
Bioneer Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩25,650.00 |
52 Week High | ₩39,100.00 |
52 Week Low | ₩23,950.00 |
Beta | -1.14 |
11 Month Change | -8.72% |
3 Month Change | -25.11% |
1 Year Change | -18.96% |
33 Year Change | -52.68% |
5 Year Change | 246.15% |
Change since IPO | 84.53% |
Recent News & Updates
Bioneer Corporation's (KOSDAQ:064550) 27% Dip In Price Shows Sentiment Is Matching Revenues
Sep 06Bioneer Corporation's (KOSDAQ:064550) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Jul 11Lacklustre Performance Is Driving Bioneer Corporation's (KOSDAQ:064550) Low P/S
Mar 06Recent updates
Bioneer Corporation's (KOSDAQ:064550) 27% Dip In Price Shows Sentiment Is Matching Revenues
Sep 06Bioneer Corporation's (KOSDAQ:064550) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Jul 11Lacklustre Performance Is Driving Bioneer Corporation's (KOSDAQ:064550) Low P/S
Mar 06Bioneer (KOSDAQ:064550) Seems To Use Debt Quite Sensibly
Mar 25Bioneer Corporation's (KOSDAQ:064550) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 15Investors Who Bought Bioneer (KOSDAQ:064550) Shares A Year Ago Are Now Up 166%
Jan 20Is Bioneer (KOSDAQ:064550) A Risky Investment?
Dec 24Here's Why We Think Bioneer's (KOSDAQ:064550) Statutory Earnings Might Be Conservative
Nov 28Shareholder Returns
A064550 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -0.4% | -0.5% | -0.5% |
1Y | -19.0% | 58.1% | 7.3% |
Return vs Industry: A064550 underperformed the KR Biotechs industry which returned 58.1% over the past year.
Return vs Market: A064550 underperformed the KR Market which returned 7.3% over the past year.
Price Volatility
A064550 volatility | |
---|---|
A064550 Average Weekly Movement | 8.4% |
Biotechs Industry Average Movement | 9.2% |
Market Average Movement | 6.8% |
10% most volatile stocks in KR Market | 12.2% |
10% least volatile stocks in KR Market | 3.6% |
Stable Share Price: A064550 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A064550's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 561 | Han-Oh Park | www.bioneer.co.kr |
Bioneer Corporation operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer and solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide function, and magnetic separation services, as well as instruments for conventional PCR, real-time PCR, sample preparation, protein synthesis, centrifuge and vortex mixer, and electrophoresis. It also provides molecular diagnosis, including MDx technologies, human diagnostics kits, MDx extraction kits, and instruments; and products for animal, aquatic-bio, mosquito-borne, and plant diseases, as well as food safety, human pathogen, and nano-bio products.
Bioneer Corporation Fundamentals Summary
A064550 fundamental statistics | |
---|---|
Market cap | ₩662.03b |
Earnings (TTM) | -₩16.20b |
Revenue (TTM) | ₩295.52b |
2.2x
P/S Ratio-40.9x
P/E RatioIs A064550 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A064550 income statement (TTM) | |
---|---|
Revenue | ₩295.52b |
Cost of Revenue | ₩69.99b |
Gross Profit | ₩225.52b |
Other Expenses | ₩241.72b |
Earnings | -₩16.20b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -627.49 |
Gross Margin | 76.32% |
Net Profit Margin | -5.48% |
Debt/Equity Ratio | 22.9% |
How did A064550 perform over the long term?
See historical performance and comparison